GET DAILY SIGNALSBraskem (BAK) Stock Slides -39% Over 30 Days on Restructuring Concerns
Key Takeaways
- Braskem's ADRs have declined roughly 39% over the past 30 days, falling from about $1.54 to around $0.94 per share.
- The sell-off extends a longer slide: BAK is down roughly 62% over the last three months from about $2.46 per share.
- An unresolved, roughly $11 billion out-of-court debt restructuring is the central driver of the decline, with proposals still unaccepted.
- Additional pressure came from an involuntary Chapter 11 filing against a financing subsidiary and a UBS downgrade to Sell.
- Heavy proposed debt-to-equity conversions create substantial dilution risk for existing shareholders.
- For additional data, explore Braskem's Price Targets, Earnings, and Forecast pages.
- For AI-driven trading signals, explore Trending AI Robots.
A Quick Look at Braskem (BAK)'s Business
Braskem S.A. is Latin America's largest petrochemical company and one of the leading producers of thermoplastic resins in the Americas. Headquartered in Camaçari, Bahia, Brazil, the company manufactures polyethylene, polypropylene, and PVC, along with basic chemicals and fuels, serving packaging, automotive, construction, agriculture, and consumer goods industries. It is also a leading producer of biopolymers, including sugarcane-derived "green" polyethylene. Braskem operates across Brazil, the United States, Mexico, and Europe, and is the largest polypropylene producer in the U.S. and a leading polyethylene producer in Mexico. Investors follow the stock for its scale and cyclical exposure to global petrochemical spreads, though its heavy debt load and an environmental liability tied to salt-mining subsidence in Maceió, Alagoas, have dominated the investment narrative. I checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30 Days and the Quarter
Over the past 30 days, Braskem's ADRs have fallen roughly 39%, from a closing level near $1.54 in late September to about $0.94. The decline accelerated sharply in the latest sessions, with the shares moving below the level that had marked the prior 52-week low of around $1.40. The period featured several failed recovery attempts, as the stock briefly traded near $1.87 in mid-October before renewed restructuring headlines drove it lower.
The quarterly picture is even weaker. From roughly $2.46 per share in late July, BAK has dropped approximately 62% over the last three months. The stock reached a 52-week high near $5.40 within the past year, underscoring the scale of the multi-month repricing as debt concerns overwhelmed the cyclical petrochemical story.
Key Drivers Behind the Latest 30-Day Move
The dominant catalyst has been the company's roughly $11 billion debt restructuring. On October 24, 2026, Braskem disclosed the details of its updated restructuring proposals — including its own plan and a competing investor proposal — while confirming that no proposal had yet been accepted. Both plans contemplate a follow-on equity offering of about $2.25 billion and significant debt-to-equity conversions, mechanics that carry heavy dilution risk for existing shareholders. I also checked this using Tickeron's AI Trend Prediction Engine to gauge potential outcomes.
The process has also drawn legal escalation. On October 21, 2026, funds affiliated with Bracebridge Capital filed an involuntary Chapter 11 petition against Braskem America Finance Company, the issuer of roughly $587 million in notes due 2041. Separately, UBS downgraded Braskem to Sell from Neutral, cutting its ADR price target to $1.50 from $4, citing Chinese capacity additions that are expected to keep petrochemical spreads under pressure into the late 2020s. The shares also fell in a broad risk-off move among Brazilian equities ahead of a Federal Reserve interest-rate decision.
Broader Pressures Over the Past Quarter
The three-month decline reflects a convergence of structural pressures. In August 2026, Braskem initiated a Brazilian "extrajudicial recovery" (recuperação extrajudicial) to restructure roughly $11 billion of debt after years of financial strain. Negotiations with creditors and controlling shareholders — Petrobras and IG4 Capital — have repeatedly stalled over how much fresh capital shareholders must commit. UBS estimates total debt near $13.2 billion, or about 95% of total capital, with negative free cash flow of roughly $1.7 billion over the trailing 12 months. Weak global petrochemical spreads, the Maceió environmental liability, and ongoing losses have compounded the balance-sheet concerns, keeping the equity under sustained pressure.
What to Watch Going Forward
The path forward hinges primarily on the restructuring. A milestone under the negotiation framework was extended to October 30, 2026, and the parties face a November 22 deadline to reach an agreement. The key variables are the size of any debt write-down, the amount of fresh capital shareholders commit, and the extent of debt-to-equity conversion — all of which determine how much value, if any, existing shareholders retain. Investors should also monitor the involuntary Chapter 11 proceeding against Braskem America Finance Company, upcoming earnings and guidance, and petrochemical spread trends as Chinese capacity additions come online. Macroeconomic conditions, including U.S. interest-rate policy and the Brazilian real, add further sensitivity. These factors present meaningful uncertainty and should be weighed carefully; this article does not constitute investment advice.
Exploring AI Tools for Volatile Names
In my analysis of names like BAK, I often turn to Tickeron's AI Daily Buy/Sell Signals for a data-driven perspective on potential entry and exit points amid restructuring uncertainty. The platform aggregates signals across thousands of tickers, which helps put individual stock moves into broader context without replacing careful fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BAK in downward trend: price dove below 50-day moving average on October 15, 2026
BAK moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 41 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In 64 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BAK's RSI Indicator exited the oversold zone, 40 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BAK just turned positive on October 23, 2026. Looking at past instances where BAK's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Following a +8.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAK advanced for three days, in 185 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (-0.054) is slightly lower than the industry average of (1.155). P/E Ratio (-0.122) is within average values for comparable stocks, (3.120). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (3.769). BAK's Dividend Yield (1.587) is considerably higher than the industry average of (0.135). P/S Ratio (0.051) is also within normal values, averaging (0.578).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of petrochemicals and other related products
Industry ChemicalsMajorDiversified
Advertisement